SRD5A2 gene polymorphism and the risk of benign prostatic hyperplasia: a meta-analysis

SRD5A2 polymophisms and BPH

Abstract

The aim of this study was to undertake a pooled data analysis for assessment of the impact of SRD5A2 polymorphisms on the risk of BPH. Literature search was performed to identify the studies that had analyzed SRD5A2 polymorphisms in association with the risk of BPH. To pool data from published case-control studies, we undertook meta-analyses on V89L polymorphism (1116 patients and 1447 controls from five studies) and (TA)n polymorphism (548 patients and 276 controls from two studies). Moderate value of I2 for between studies genotype comparison (P heterogeneity = 0.204, Q = 7.232, df (Q) = 5, I2 = 30.867) showed the presence of low level of true heterogeneity. The meta-analysis on V89L polymorphism using either of two analysis models suggested that there is no association of this substitution with BPH risk (fixed effect model: OR=1.119 (CI = 0.95-1.31), p-value = 0.168; random effects model: OR=1.118 (CI = 0.87-1.44), p-value = 0.389). Nevertheless, the frequency of VV was higher in the cases. Similarly, (TA)n repeats distribution showed no significant difference between cases and controls. Meta-analysis using either of the two analysis models suggested that there is no association of (TA)n repeat length with BPH risk (fixed effect model: OR=1.062 (CI = 0.73-1.54), p-value= 0.751; random effect model: OR=1.062 (CI = 0.73-1.54), p-value= 0.751). In conclusion, V89L and (TA)n repeat polymorphisms in the SRD5A2 gene do not significantly affect the risk of BPH.